Ghirardelli Issues Recall for Powdered Beverage Mixes Over Salmonella Risk

Massive Pet Food Recall Affects Over 400,000 Pounds Across Multiple States

A significant recall of over 400,000 pounds of pet food has been announced, impacting several states, including Texas. The affected products were manufactured between July 17, 2025, and December 23, 2025, with an additional batch produced on March 31, 2026. This recall is crucial for pet owners to ensure the safety and health of their animals, as consuming contaminated food can lead to serious health issues. Pet owners should check their supplies and dispose of any recalled products immediately to prevent harm to their pets.

Understanding 'Ghost Fat': A New Phenomenon from Weight-Loss Injections

Individuals who have used injectable weight-loss medications are reporting a phenomenon known as 'ghost fat.' This term refers to the lingering behaviors and habits that persist even after significant weight loss, as users may subconsciously continue actions associated with their previous larger size. This psychological effect can impact their ongoing weight management and self-image. Understanding 'ghost fat' is crucial for both users and healthcare providers to address potential challenges in maintaining a healthy lifestyle post-treatment.

Understanding 'Ghost Fat': A New Phenomenon from Weight-Loss Injections

Recent findings reveal that individuals using injectable weight-loss medications may experience a phenomenon known as 'ghost fat.' This term refers to the lingering psychological effects and behaviors that persist even after significant weight loss. As people shed pounds, they might unconsciously maintain habits associated with their previous larger size, impacting their mental health and body image. This issue highlights the importance of addressing both physical and psychological aspects of weight loss treatments. Awareness of 'ghost fat' can help those affected navigate their post-weight-loss journey more effectively.

Uncertainty Surrounds FDA Decision on Moderna's mRNA Flu Vaccine for Seniors

An FDA advisory panel has recommended the use of Moderna's mRNA flu vaccine for older adults, but the absence of a permanent vaccine chief and commissioner raises questions about the decision-making process. This recommendation is significant as it could enhance flu prevention among vulnerable populations, particularly seniors who are at higher risk for severe illness. The timeline for a final decision remains unclear, leaving many in the healthcare community and potential vaccine recipients in anticipation of the next steps.